不同阶段HER2阳性乳腺癌分层治疗的要点解析

Key issues in stratified treatment of HER2 positive breast cancer at different stages

近年来抗HER2药物临床研究不断取得突破性进展,显著改善了HER2阳性乳腺癌患者的预后,改变了乳腺癌的诊疗模式。2020版《中国临床肿瘤学会(CSCO)乳腺癌诊疗指南》在HER2阳性乳腺癌的术前新辅助治疗、术后辅助治疗以及复发转移治疗部分做出重要更新,针对不同阶段患者特征分层给予治疗推荐,规范乳腺癌临床诊疗,提高患者生存率,改善患者生存质量。

In recent years,the clinical research of anti-HER2 drugs has made many breakthroughs,which has significantly improved the prognosis of HER2 positive breast cancer patients and changed the diagnosis and treatment mode of breast cancer.The 2020 edition of the Chinese Society of Clinical Oncology(CSCO)breast cancer diagnosis and treatment guidelines has made important updates to the pre-operative neoadjuvant treatment,postoperative adjuvant treatment,and recurrence and metastasis management of HER2 positive breast cancer,given treatment recommendations for patients with different stages of breast cancer,and standardized the clinical diagnosis and treatment of this malignancy,aiming to improve the survival rate and the quality of life of patients.